Primary Site >> Stomach Cancer

Gene >> CYP3A4

Journal: Br J Cancer. 1998 Apr;77(7):1040-4.
Title: Enhanced expression of cytochrome P450 in stomach cancer.
Author: Murray, G I|Taylor, M C|Burke, M D|Melvin, W T
PMID: 9569036
Journal: BMC Cancer. 2007 Jul 2;7:118.
Title: Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Author: Gervasini, Guillermo|Garcia-Martin, Elena|Ladero, Jose M|Pizarro, Rosa|Sastre, Javier|Martinez, Carmen|Garcia, Monserrat|Diaz-Rubio, Manuel|Agundez, Jose A G
PMID: 17605821
Journal: BMC Cancer. 2010 Mar 1;10:73.
Title: Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines.
Author: Junnila, Siina|Kokkola, Arto|Karjalainen-Lindsberg, Marja-Liisa|Puolakkainen, Pauli|Monni, Outi
PMID: 20187983
Journal: Int J Oncol. 2010 Nov;37(5):1219-28.
Title: Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.
Author: Lo Nigro, Cristiana|Monteverde, Martino|Riba, Michela|Lattanzio, Laura|Tonissi, Federica|Garrone, Ornella|Heouaine, Abdelhamid|Gallo, Fabio|Ceppi, Marcello|Borghi, Felice|Comino, Alberto|Merlano, Marco
PMID: 20878069
Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Aug;33(8):1098-101.
Title: [Effect of jianpi liqi recipe on mRNA expressions of TP, DPD, and CYP3A4 in mice with human gastric cancer transplanted tumor].
Author: Huang, Ting|Yang, Xue-fei|Li, Yong|Zhang, Zhi-di|Huang, Ling|Zhang, Jian-gang|Zhang, Xiao-li
PMID: 24325062
Journal: Int J Biochem Cell Biol. 2016 Mar;72:73-88.
Title: Cross-talk between EPAS-1/HIF-2alpha and PXR signaling pathway regulates multi-drug resistance of stomach cancer cell.
Author: Zhao, Jiuda|Bai, Zhenzhong|Feng, Fan|Song, Erlin|Du, Feng|Zhao, Junhui|Shen, Guoshuang|Ji, Faxiang|Li, Guoyuan|Ma, Xinfu|Hang, Xingyi|Xu, Binghe
PMID: 26783937
Journal: J Med Chem. 2016 Aug 11;59(15):7066-74.
Title: Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazo l-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
Author: Ugolini, Antonio|Kenigsberg, Mireille|Rak, Alexey|Vallee, Francois|Houtmann, Jacques|Lowinski, Maryse|Capdevila, Cecile|Khider, Jean|Albert, Eva|Martinet, Nathalie|Nemecek, Conception|Grapinet, Sandrine|Bacque, Eric|Roesner, Manfred|Delaisi, Christine|Cal
PMID: 27355974
Journal: Pharmacogenomics J. 2017 Oct;17(5):441-451.
Title: Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
Author: Meulendijks, D|Rozeman, E A|Cats, A|Sikorska, K|Joerger, M|Deenen, M J|Beijnen, J H|Schellens, J H M
PMID: 27995989
Journal: J Clin Pharmacol. 2017 Oct 2.
Title: Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.
Author: Liu, Xiaoyun|Zhang, Yifan|Chen, Qian|Zhan, Yan|Wang, Quanren|Hu, Chaoying|Yu, Chen|Guo, Zitao|Chen, Xiaoyan|Zhong, Dafang
PMID: 28967981
Journal: Toxicol Lett. 2018 Nov;297:1-7.
Title: Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450.
Author: Bao, Su-Su|Wen, Jian|Zheng, Xiang|Zhou, Quan|Qu, Gao-Er|Chen, Ming-Jing|Hu, Guo-Xin
PMID: 30138636